Surge in prevalence of cancer across geographies, rise in demand for ideal therapeutics for cancer treatment, favorable reimbursement policies offered by manufacturers & insurance providers in some countries, and surge in awareness of checkpoint inhibitors for the treatment of cancer due to positive results are the factors driving the growth of the global immune checkpoint inhibitors market.
As per the report published by Allied Market Research, the global immune checkpoint inhibitors market was valued at $10.56 billion in 2017 and is estimated to reach $56.53 billion by 2025, registering a CAGR of 20.1% from 2018 to 2025.
Rise in prevalence of cancer across geographies, high demand for ideal therapeutics for cancer treatment, favorable reimbursement policies offered by manufacturers & insurance providers in some countries, and surge in awareness of checkpoint inhibitors for the treatment of cancer due to positive results are the factors driving the growth of the global immune checkpoint inhibitors market. Furthermore, rise in geriatric population and surge in technological advancements in screening & diagnosis of cancer fuel the market growth. On the other hand, high cost of treatment associated with immune checkpoint inhibitors impedes the growth up to a certain extent. However, upsurged number of pipeline drugs and untapped opportunities in the emerging markets would provide lucrative growth in the upcoming future.
Click Here To Access The Sample Report @ https://www.alliedmarketresearch.com/request-sample/3723
On the basis of applications, the lung cancer segment dominated the global market in 2017 accounting for 45% of the total market share. The segment is expected to continue its dominance throughout the study period. However, the bladder cancer segment is expected to register the fastest CAGR of 21.1% through 2025.
On the basis of types, the PD-1 inhibitor segment contributed 82% of the total market share in 2017. The segment is expected to maintain the dominance throughout the study period. On the other hand, the PD-L1 inhibitor segment would grow at the fastest CAGR of 34.2% through 2025.
Based on geography, North America contributed nearly two-thirds of the total market share in 2017. The region is expected to continue its dominance throughout the study period. On the other hand, Asia-Pacific would grow at the fastest CAGR of 22.1% during 2017-2025.
For Purchase Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/3723
Leading market players–
The leading companies of the global immune checkpoint inhibitors market include F. Hoffmann-La Roche Ltd. (Genentech, Inc.), (Checkpoint Therapeutics, Inc.), Immutep Limited, Merck & Co., Inc., Fortress Biotech, Merck KGaA (EMD Serono, Inc.), Novartis AG, AstraZeneca PLC., Eli Lilly and Company (ARMO Biosciences.), Inc., Pfizer Inc., and Bristol-Myers Squibb Company.
| Report Attribute | Details |
| Market size available for years | 2017-2025 |
| Base year considered | 2018 |
| Forecast period | 2018-2025 |
| Forecast units | Value (USD) |
| Segments covered | Type, Application and Region |
| Geographies covered | North America, Europe, Asia-Pacific, LAMEA |
Related Reports:
Immunotherapy Drugs Market by Therapy Area [Cancer (Solid Tumor and Malignant), Autoimmune & Inflammatory Diseases, Infectious Diseases, and Others], Type of Drugs [Monoclonal Antibodies, Adult Vaccines (Preventive Vaccines and Therapeutic Vaccines), Checkpoint Inhibitors, Interferons Alpha & Beta, Interleukins, and Others] – Global Opportunity Analysis and Industry Forecast, 2019-2026
Beta-lactam and Beta-lactamase Inhibitors Market by Drug Class (Penicillin, Cephalosporin, Carbapenem, Monobactam, and Combination), Disease (Urinary Tract Infection, Respiratory Infection, Skin Infection, Complicated Urinary Tract Infection (cUTI), Complicated Intra-Abdominal Infections (cIAI), Nosocomial Pneumonia, Blood Stream Infection, and Other Diseases), and Route of Administration (Oral, Intravenous, and Other Route of Administrations): Global Opportunity Analysis and Industry Forecast, 2019–2028
Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research
Follow Us on Twitter: https://twitter.com/marketresearcht